Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

VERTEX PHARMACEUTICALS INC / MA Director's Dealing 2014

Nov 3, 2014

29864_dirs_2014-11-03_13cf6c9b-344f-4464-8ac9-9f1995b2a6f1.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2014-10-30

Reporting Person: Sachdev Amit (EVP, Policy, Access & Value)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2014-10-30 Common Stock A 40000 $0.01 Acquired 78671 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 882 Indirect

Footnotes

F1: Performance-based retention award that will vest if performance objectives are achieved prior to November 15, 2019. The award will vest on October 30, 2017 (or, if later, the day following the earnings release for the third quarter of 2017) if the Company achieves positive EBITDA for the 12-month period ending September 30, 2017. Between January 1, 2018 and November 15, 2019, if the Company achieves positive EBITDA for a 12-month period ending on a calendar quarter, the award will vest on the day following the applicable earnings release.